Suppr超能文献

人骨髓间充质干细胞在针对病毒或肿瘤相关抗原的HLA-I类限制性T细胞应答中的免疫原性。

Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens.

作者信息

Morandi Fabio, Raffaghello Lizzia, Bianchi Giovanna, Meloni Francesca, Salis Annalisa, Millo Enrico, Ferrone Soldano, Barnaba Vincenzo, Pistoia Vito

机构信息

Laboratory of Oncology, G. Gaslini Children's Hospital, Genoa, Italy.

出版信息

Stem Cells. 2008 May;26(5):1275-87. doi: 10.1634/stemcells.2007-0878. Epub 2008 Feb 21.

Abstract

Human mesenchymal stem cells (MSC) are immunosuppressive and poorly immunogenic but may act as antigen-presenting cells (APC) for CD4(+) T-cell responses; here we have investigated their ability to serve as APC for in vitro CD8(+) T-cell responses. MSC pulsed with peptides from viral antigens evoked interferon (IFN)-gamma and Granzyme B secretion in specific cytotoxic T lymphocytes (CTL) and were lysed, although with low efficiency. MSC transfected with tumor mRNA or infected with a viral vector carrying the Hepatitis C virus NS3Ag gene induced cytokine release but were not killed by specific CTL, even following pretreatment with IFN-gamma. To investigate the mechanisms involved in MSC resistance to CTL-mediated lysis, we analyzed expression of human leukocyte antigen (HLA) class I-related antigen-processing machinery (APM) components and of immunosuppressive HLA-G molecules in MSC. The LMP7, LMP10, and ERp57 components were not expressed and the MB-1 and zeta molecules were downregulated in MSC either unmanipulated or pretreated with IFN-gamma. Surface HLA-G was constitutively expressed on MSC but was not involved in their protection from CTL-mediated lysis. MSC supernatants containing soluble HLA-G (sHLA-G) inhibited CTL-mediated lysis, whereas those lacking sHLA-G did not. The role of sHLA-G in such inhibition was unambiguously demonstrated by partial restoration of lysis following sHLA-G depletion from MSC supernatants. In conclusion, human MSC can process and present HLA class I-restricted viral or tumor antigens to specific CTL with a limited efficiency, likely because of some defects in APM components. However, they are protected from CTL-mediated lysis through a mechanism that is partly sHLA-G-dependent.

摘要

人间充质干细胞(MSC)具有免疫抑制作用且免疫原性较弱,但可能作为抗原呈递细胞(APC)参与CD4(+) T细胞反应;在此,我们研究了它们作为APC参与体外CD8(+) T细胞反应的能力。用病毒抗原肽脉冲处理的MSC可在特异性细胞毒性T淋巴细胞(CTL)中诱发干扰素(IFN)-γ和颗粒酶B分泌,并且会被裂解,尽管效率较低。用肿瘤mRNA转染或感染携带丙型肝炎病毒NS3Ag基因的病毒载体的MSC可诱导细胞因子释放,但即使在用IFN-γ预处理后也不会被特异性CTL杀死。为了研究MSC抵抗CTL介导的裂解所涉及的机制,我们分析了人间白细胞抗原(HLA)I类相关抗原加工机制(APM)成分以及MSC中免疫抑制性HLA-G分子的表达。LMP7、LMP10和ERp57成分未表达,MB-1和ζ分子在未处理或用IFN-γ预处理的MSC中下调。表面HLA-G在MSC上组成性表达,但不参与其免受CTL介导的裂解的保护。含有可溶性HLA-G(sHLA-G)的MSC上清液可抑制CTL介导的裂解,而缺乏sHLA-G的上清液则无此作用。从MSC上清液中去除sHLA-G后裂解作用部分恢复,明确证明了sHLA-G在这种抑制作用中的作用。总之,人间MSC能够以有限的效率将HLA I类限制性病毒或肿瘤抗原加工并呈递给特异性CTL,这可能是由于APM成分存在一些缺陷。然而,它们通过部分依赖sHLA-G的机制免受CTL介导的裂解。

相似文献

5
Recognition of breast cancer-associated peptides by tumor-reactive, HLA-class I restricted allogeneic cytotoxic T lymphocytes.
Int J Cancer. 1999 May 17;81(4):607-15. doi: 10.1002/(sici)1097-0215(19990517)81:4<607::aid-ijc17>3.0.co;2-x.
7
Soluble HLA class I molecules/CD8 ligation trigger apoptosis of CD8+ cells by Fas/Fas-ligand interaction.
ScientificWorldJournal. 2002 Feb 12;2:421-3. doi: 10.1100/tsw.2002.122.
9
HLA-E-restricted recognition of human cytomegalovirus by a subset of cytolytic T lymphocytes.
Hum Immunol. 2004 May;65(5):437-45. doi: 10.1016/j.humimm.2004.02.001.

引用本文的文献

1
State-of the-art and future perspective in co-culture systems for tendon engineering.
Biomater Biosyst. 2025 Mar 5;17:100110. doi: 10.1016/j.bbiosy.2025.100110. eCollection 2025 Mar.
2
Therapeutic potential of mesenchymal stem cells for fungal infections: mechanisms, applications, and challenges.
Front Microbiol. 2025 Jan 30;16:1554917. doi: 10.3389/fmicb.2025.1554917. eCollection 2025.
3
Fate and long-lasting therapeutic effects of mesenchymal stromal/stem-like cells: mechanistic insights.
Stem Cell Res Ther. 2025 Feb 4;16(1):33. doi: 10.1186/s13287-025-04158-z.
4
Mesenchymal stem cell therapy as a game-changer in liver diseases: review of current clinical trials.
Stem Cell Res Ther. 2025 Jan 6;16(1):3. doi: 10.1186/s13287-024-04127-y.
5
Anti-inflammatory effect of dental pulp stem cells.
Front Immunol. 2023 Nov 23;14:1284868. doi: 10.3389/fimmu.2023.1284868. eCollection 2023.
6
Interaction between Mesenchymal Stem Cells and Immune Cells during Bone Injury Repair.
Int J Mol Sci. 2023 Sep 23;24(19):14484. doi: 10.3390/ijms241914484.
7
Mesenchymal Stem Cell in Pancreatic Islet Transplantation.
Biomedicines. 2023 May 11;11(5):1426. doi: 10.3390/biomedicines11051426.
8
Mesenchymal Stem Cells and Their Exocytotic Vesicles.
Int J Mol Sci. 2023 Jan 20;24(3):2085. doi: 10.3390/ijms24032085.
10
Combination of Stem Cells with Chinese Herbs for Secondary Depression in Neurodegenerative Diseases Based on Traditional Chinese Medicine Theories.
Evid Based Complement Alternat Med. 2022 Mar 3;2022:6847917. doi: 10.1155/2022/6847917. eCollection 2022.

本文引用的文献

1
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis.
Nature. 2007 Oct 4;449(7162):557-63. doi: 10.1038/nature06188.
2
Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G.
Transplantation. 2007 Jul 27;84(2):231-7. doi: 10.1097/01.tp.0000267918.07906.08.
3
Immunomodulatory properties of mesenchymal stromal cells.
Blood. 2007 Nov 15;110(10):3499-506. doi: 10.1182/blood-2007-02-069716. Epub 2007 Jul 30.
7
Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes.
J Leukoc Biol. 2007 Oct;82(4):887-93. doi: 10.1189/jlb.0307140. Epub 2007 Jul 3.
8
Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells.
Leukemia. 2007 Aug;21(8):1733-8. doi: 10.1038/sj.leu.2404777. Epub 2007 May 31.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验